Taking MegaSporeBiotic (for at least 30 days pre-COVID-19 infection) Improves Recovery Times, Mitigates Symptoms, in Those with Mild Cases
I’ve wondered about the role of probiotics in SARS-Cov-2 infections. Could a diverse and well-populated gut microbiome “discourage” the virus from taking hold in the body, resulting in a COVID-19 infection?
Could a probiotic like MegaSporeBiotic, which is clinically shown to support a healthy gut mucosal layer, help people have a better immune response to SARS-Cov-2 and possibly have fewer disease symptoms?
A new peer reviewed study highlighted that patients who were taking MegaSporeBiotic for at least 30 days prior to a SARS-Cov-2 infection, and had a mild COVID-19 infection, experienced a shorter recovery time (6.6 days compared to 8.5 days in placebo) and faster fever resolution (MegaSporeBiotic group was 1.6x more likely to have their fever resolved faster than the control group).
In addition, those in the MegaSporeBiotic group experienced significantly less GI symptoms (diarrhea, pain, etc.).
If you’d like to read the study:
Ongoing Treatment with a Spore-Based Probiotic Containing Five Strains of Bacillus Improves Outcomes of Mild COVID-19, Nutrients, January 2023.
Key Takeaways of the Study:
- Ongoing treatment with the spore-based probiotic contributes to a better clinical outcome for mild COVID-19, including fewer digestive symptoms, faster symptom resolution and faster resolution of fever.
- Together with current therapies, probiotic supplementation may play a role in COVID-19 disease mitigation and improved patient quality of life.
- Consistently taking a spore-based probiotic before and during infection with SARS-CoV-2 positively impacts the course of COVID-19.
I consider a probiotic such as MegaSporeBiotic to be foundational to gut health. Strong gut health is key to maintaining a healthy immune system and overall health and to being prepared for health challenges.
